Registration Dossier
Registration Dossier
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 619-447-3 | CAS number: 99607-70-2
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data

Repeated dose toxicity: oral
Administrative data
- Endpoint:
- sub-chronic toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 10 May 1988 to 12 August 1988
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- other: GLP compliant, guideline study, available as unpublished report, no restrictions, fully adequate for assessment
Cross-reference
- Reason / purpose for cross-reference:
- reference to same study
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 1 989
- Report date:
- 1989
Materials and methods
Test guideline
- Qualifier:
- equivalent or similar to guideline
- Guideline:
- OECD Guideline 408 (Repeated Dose 90-Day Oral Toxicity Study in Rodents)
- Deviations:
- not applicable
- Principles of method if other than guideline:
- Not applicable
- GLP compliance:
- yes
- Limit test:
- no
Test material
- Reference substance name:
- heptan-2-yl [(5-chloroquinolin-8-yl)oxy]acetate
- EC Number:
- 619-447-3
- Cas Number:
- 99607-70-2
- Molecular formula:
- C18H22ClNO3
- IUPAC Name:
- heptan-2-yl [(5-chloroquinolin-8-yl)oxy]acetate
- Details on test material:
- - Name of test material (as cited in study report): CGA185072 technical
- Analytical purity: 91.6%
Constituent 1
Test animals
- Species:
- rat
- Strain:
- other: Tif: RAIf rat, Sprague-Dawley derived
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Age at study initiation: 4-5 weeks old
- Weight at study initiation: 101.9 - 131.7 g (males), 102.8 - 131.9 g (females)
IN-LIFE DATES: From: 10.05.1988 To: 12.08.1988
Administration / exposure
- Route of administration:
- oral: feed
- Vehicle:
- other: diet
- Details on oral exposure:
- DIET PREPARATION
- Rate of preparation of diet (frequency): monthly
- Mixing appropriate amounts with (Type of food): the test material was admixed to standard rodent diet. As it was found that pelleting of food resulted in a loss of test material, the treated food was used in pulverized form - Analytical verification of doses or concentrations:
- yes
- Details on analytical verification of doses or concentrations:
- Analyses were done with the first and the last batch prepared using a HPLC method.
The analytically determined concentrations ranged from 92.8 to 102.3% of the nominal concentrations. The food mixes were homogeneous (-6% to +4% of mean value) and stable at room temperature over at least 35 days. The analytical data thus indicated that the mixing procedure was adequate and that the variance between nominal and actual dosage was acceptable. - Duration of treatment / exposure:
- The rats were exposed for 85 days to treated diet and some were retained untreated (fed normal diet only) for a recovery period that ended on day 114
- Frequency of treatment:
- Continuous in diet
Doses / concentrationsopen allclose all
- Remarks:
- Doses / Concentrations:
0, 30, 150, 1000, 6000 ppm
Basis:
nominal in diet
- Remarks:
- Doses / Concentrations:
2.039, 9.66, 63.89 and 384.2 mg/kg bw/day in males and 2.036, 10.23, 68.51 and 407.3 mg/kg bw/day in females
Basis:
actual ingested
- No. of animals per sex per dose:
- 10
- Control animals:
- yes, plain diet
- Details on study design:
- 10 males and 10 females per test group plus 10 males and 10 females for each recovery group
Examinations
- Observations and examinations performed and frequency:
- CAGE SIDE OBSERVATIONS: Yes
- Time schedule: animals were checked twice daily for signs of toxicity and mortality
BODY WEIGHT: Yes
- Time schedule for examinations: body weight were taken pretest and weekly during the treatment period.
FOOD CONSUMPTION AND COMPOUND INTAKE (if feeding study): Yes
- Compound intake calculated as time-weighted averages from the consumption and body weight gain data: Yes
- Food and water consumption were recorded weekly
OPHTHALMOSCOPIC EXAMINATION: Yes
- Time schedule for examinations: pretest and at the end of the treatment (day 85) or recovery period (day 114)
- Dose groups that were examined: control and high dose group animals
HAEMATOLOGY/CLINICAL CHEMISTRY: Yes
- Time schedule for collection of blood: blood was collected from surviving animals at the end of the treatment period (n=20) and at the end of the recovery period (n=10)
- Anaesthetic used for blood collection: no data
- Animals fasted: Yes (overnight)
- A full guideline compliant list of haematology and clinical chemistry parameters was investigated for terminal and recovery phase blood samples - Sacrifice and pathology:
- GROSS PATHOLOGY: Yes
- selected organs weighed (all animals)
HISTOPATHOLOGY: Yes
- The sole decedent in the high dose group, all animals killed at the scheduled treatment termination or at the end of the recovery phase were subject to necropsy in accordance with test guidelines and preservation and preparation of a full list of tissues for histopathology - Statistics:
- Univariate standard methods were applied to the data. Each treated group was compared to the control group (Lepage test). In addition a trend test (Jonckheere test) was applied considering all groups.
Results and discussion
Results of examinations
- Clinical signs:
- effects observed, treatment-related
- Mortality:
- mortality observed, treatment-related
- Body weight and weight changes:
- no effects observed
- Food consumption and compound intake (if feeding study):
- no effects observed
- Water consumption and compound intake (if drinking water study):
- effects observed, treatment-related
- Ophthalmological findings:
- no effects observed
- Haematological findings:
- effects observed, treatment-related
- Clinical biochemistry findings:
- effects observed, treatment-related
- Urinalysis findings:
- effects observed, treatment-related
- Behaviour (functional findings):
- not examined
- Organ weight findings including organ / body weight ratios:
- effects observed, treatment-related
- Gross pathological findings:
- effects observed, treatment-related
- Histopathological findings: non-neoplastic:
- effects observed, treatment-related
- Histopathological findings: neoplastic:
- not examined
- Details on results:
- CLINICAL SIGNS AND MORTALITY
- One male at 6000 ppm died
BODY WEIGHT AND WEIGHT GAIN
- Body weight gains for high dose males were slightly reduced and the females were slightly lighter than controls but no clear dose relationship was established
WATER CONSUMPTION
- Water consumption was higher (+20%) for the high dose group compared with control but returned to normal when treated diet was withdrawn in the recovery phase
HAEMATOLOGY
- High dose males (6000 ppm) showed a slight prolongation of the prothrombin time, which was not detected in the recovery group. In the absence of any other haematological changes, this isolated finding is considered to be of doubtful toxicological significance
CLINICAL CHEMISTRY
- The plasma glucose level was lower in males treated at 6000 ppm, higher bilirubin levels were found in males treated at 1000 and 6000 ppm, lower cholesterol levels were noted in the top dose group females. All parameters were normal at the end of the recovery period
URINALYSIS
- The high dose group males excreted greater volumes of less concentrated urine (reduced relative density) compared with other groups. This was consistent with higher water intake by this group.
ORGAN WEIGHTS
- Mean absolute and relative liver weights were reduced in males and females treated at 1000 and 6000 ppm. A trend for decreased kidney weights was noted in the males treated at 1000 ppm and above and - as a slight tendency - also in the top dose group females. The recovery groups showed no differences between treated groups and controls
GROSS PATHOLOGY
- One high dose (6000 ppm) male died on day 63. Post mortem investigations revealed acute nephritis, hydronephrosis with multifocal calcifications and inflammation of the urinary bladder. The findings were considered to be treatment-related.
- For animals terminated at the end of treatment with test diet, dilated kidneys were seen in two males from the high dose group (6000 ppm), one of these was the decedent that had died prematurely. In the recovery group, four additional males from the top dose group were found with the same diagnosis and one male from the same group had a dilated urinary bladder. No other notable pathological changes were evident
HISTOPATHOLOGY: NON-NEOPLASTIC
- Hydronephrosis was evident at the end of treatment for 3/10 males treated at 6000 ppm. The same observation was made in 4/9 males from the recovery group and in the individual which died prematurely. The finding was accompanied by inflammatory and fibrotic changes in the renal cortex. Hyperplasia and inflammatory cell infiltrations of the urinary bladder were found in 1/10 males at the first sacrifice, in the male which had died and in 4/9 males from the recovery group. The same observation was made in one male treated at 1000 ppm
Effect levels
- Dose descriptor:
- NOAEL
- Effect level:
- 150 ppm
- Sex:
- male/female
- Basis for effect level:
- other: see 'Remark'
Target system / organ toxicity
- Critical effects observed:
- not specified
Any other information on results incl. tables
The analytically determined concentrations ranged from 92.8 to 102.3% of the nominal concentrations. The food mixes were homogeneous (-6% to +4% of mean value) and stable at room temperature over at least 35 days. The analytical data thus indicated that the mixing procedure was adequate and that the variance between nominal and actual dosage was acceptable.
The calculated mean daily intake of cloquintocet-mexyl based on the analytically determined concentrations was 2.039, 9.66, 63.89 and 384.2 mg/kg bw/day in males and 2.036, 10.23, 68.51 and 407.3 mg/kg bw/day in females.
Table 1: Cloquintocet-mexyl: 3 month toxicity study in rats - Mean body weight and body weight gain
ppm |
0 |
30 |
150 |
100 |
6000 |
Males Pretest (g) |
118.9 |
120.4 |
115.8 |
117.2 |
119.4 |
Week 13 |
477.9 |
512.8 |
473.2 |
475.9 |
456.3 |
Body weight gain pretest-week 13 |
359 |
392.4 |
357.4 |
358.7 |
336.9 |
(% of control) |
|
|
|
|
94 |
Week 17 |
517.6 |
561.7 |
505.4 |
535.6 |
499.1 |
Females |
|
|
|
|
|
Week 13 |
115.5 |
113.4 |
114.9 |
111.2 |
115.0 |
Body weight gain pretest-week 13 (% of control) |
309.2 |
292.2 |
297.8 |
297.8 |
294.9 |
Week 17 |
327.4 |
305.5 |
314.0 |
314.0 |
315.5 |
Table 2: Cloquintocet-mexyl: 3 month toxicity study in rats - Blood chemistry data (week 14)
Males |
Females |
|||||||||
ppm |
0 |
30 |
150 |
1000 |
6000 |
0 |
30 |
150 |
1000 |
6000 |
Glucose (mmol/l) |
8.47 |
8.19 |
8.49 |
8.17 |
7.69* |
7.23 |
7.22 |
7.08 |
6.86* |
6.89 |
Bilirubin (mmol/l) |
3.23 |
2.92 |
3.13 |
3.91** |
4.15** |
3.14 |
3.07 |
2.93 |
3.37** |
3.47** |
*: p 0.05, **: p 0.01, Lepage test |
Table 3: Cloquintocet-mexyl: 3 month toxicity study in rats – Organ weights
Dose level (ppm) |
0 |
30 |
150 |
1000 |
6000 |
Males |
|
|
|
|
|
Liver weight (g |
18.63 |
18.19 |
17.60 |
15.36* |
14.79* |
Liver to b.w. ratio |
41.04 |
37.42 |
38.37 |
35.25* |
34.67* |
Kidney weight (g) |
2.926 |
2.895 |
2.774 |
2.581* |
2.634 |
Kidney to b.w. ratio |
6.430 |
5.987 |
6.092* |
5.924* |
6.202 |
Females |
|
|
|
|
|
Liver weight (g |
10.84 |
9.774 |
10.36 |
9.493 |
9.090* |
Liver to b.w. ratio |
38.58 |
35.79 |
37.06 |
35.20 |
33.43 |
Kidney weight (g) |
1.867 |
1.802 |
1.907 |
1.824 |
1.693 |
Kidney to b.w. ratio |
6.645 |
6.620 |
6.825 |
6.760 |
6.233 |
*: p 0.05, **: p 0.01, Lepage test |
Table 4: Cloquintocet-mexyl: 3 month toxicity study in rats - Histopathology data
|
Males |
Females |
||||||||
ppm |
0 |
30 |
150 |
1000 |
6000 |
0 |
30 |
150 |
1000 |
6000 |
Kidney |
|
|
|
|
|
|
|
|
|
|
Hydronephrosis: 14 weeks |
0 |
0 |
0 |
0 |
3 |
0 |
0 |
0 |
0 |
0 |
18 weeks |
0 |
0 |
0 |
0 |
4 |
0 |
0 |
0 |
0 |
0 |
Urinary bladder |
|
|
|
|
|
|
|
|
|
|
Hyperplasia |
|
|
|
|
|
|
|
|
|
|
14 weeks |
0 |
0 |
0 |
1 |
1 |
0 |
0 |
0 |
0 |
0 |
18 weeks |
0 |
0 |
0 |
0 |
4 |
0 |
0 |
0 |
0 |
0 |
Inflammatory cell infiltration |
|
|
|
|
|
|
|
|
|
|
14 weeks |
0 |
0 |
0 |
1 |
1 |
0 |
0 |
0 |
0 |
0 |
18 weeks |
0 |
0 |
0 |
0 |
4 |
0 |
0 |
0 |
0 |
0 |
Applicant's summary and conclusion
- Conclusions:
- Based on the effects seen in the bladder of males the NOAEL was 150 ppm, equivalent to a mean daily intake of 9.66 mg/kg in males and 10.2 mg/kg in females
- Executive summary:
Groups of male and female Tif: RAIf, Sprague-Dawley derived rats were treated for three months with cloquintocet-mexyl via dietary admixture and additional animals were retained for a post-treatment recovery phase to check for reversibility of effects. The dose levels used were 0 (control), 30, 150, 1000 and 6000 ppm. The study methods were compliant with the OECD test guideline and a full list of parameters of systemic toxicity was investigated.
Subchronic dietary treatment for 3 month with cloquintocet-mexyl caused mortality in one male rat at a high dose of 6000 ppm. In males rats the target organs of toxicity were the kidney, which showed hydronephrosis and chronic inflammatory changes, and the urinary bladder indicated by hyperplasia and inflammation. Based on the effects seen in the bladder of males the NOAEL was 150 ppm, equivalent to a mean daily intake of 9.66 mg/kg in males and 10.2 mg/kg in females.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.

EU Privacy Disclaimer
This website uses cookies to ensure you get the best experience on our websites.